{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:44:29Z","timestamp":1763412269482,"version":"3.45.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Radioactive iodine therapy (RIT) for Graves\u2019 disease (GD) often involves antithyroid drugs (ATDs) withdrawal and the exacerbation of thyrotoxicosis. This study investigated the efficacy of RIT with concomitant ATDs (CATD) versus temporary ATDs withdrawal in Japanese patients with GD, a population with high iodine intake according to global standards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This retrospective observational study included 179 patients with GD who visited the University of Tsukuba Hospital. Propensity score matching (balancing age, sex, thyroid weight, free T4) created comparable groups of 15 patients each: CATD(-) withdrawing ATDs and CATD(+) continuing ATDs during RIT. Cure was defined as hypothyroidism or euthyroidism achieved without ATDs or potassium iodide. Post-matching, the CATD(+) group received significantly higher baseline ATD doses (median 600 vs. 200\u00a0mg\/day propylthiouracil-equivalent;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.008). The cure rate within 12 months after RIT was significantly higher in the CATD(-) group than in the CATD(+) group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912 [80.0%] vs.\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094 [26.7%];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). CATD may be associated with a lower cure rate within 12 months compared with standard RIT involving temporary ATD discontinuation. We suggest further prospective studies to confirm the efficacy of radioactive iodine therapy with concomitant antithyroid drugs in high iodine intake country.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-025-07558-9","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:28:46Z","timestamp":1763047726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of radioactive iodine therapy with concomitant antithyroid drugs in Japanese patients with Graves\u2019 disease: a retrospective observational study"],"prefix":"10.1186","volume":"18","author":[{"given":"Yoshinori","family":"Osaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fukazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikako","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Sekiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Shimano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"5","key":"7558_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1210\/er.2009-0041","volume":"31","author":"GE Krassas","year":"2010","unstructured":"Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702\u201355.","journal-title":"Endocr Rev"},{"issue":"1","key":"7558_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1172\/JCI101276","volume":"21","author":"S Hertz","year":"1942","unstructured":"Hertz S, Roberts A. Radioactive iodine as an indicator in thyroid Physiology. V. The use of radioactive iodine in the differential diagnosis of two types of graves\u2019 disease. J Clin Invest. 1942;21(1):31\u20132.","journal-title":"J Clin Invest"},{"issue":"12","key":"7558_CR3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jama.1968.03140380059014","volume":"205","author":"EL Saenger","year":"1968","unstructured":"Saenger EL, Thoma GE, Tompkins EA. Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the cooperative thyrotoxicosis therapy Follow-Up study. JAMA. 1968;205(12):855\u201362.","journal-title":"JAMA"},{"issue":"3","key":"7558_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/1535370215602784","volume":"241","author":"Y Ding","year":"2016","unstructured":"Ding Y, Xing J, Fang Y, Wang Y, Zhang Y, Long Y. 131I therapy for 345 patients with refractory severe hyperthyroidism: without antithyroid drug pretreatment. Exp Biol Med (Maywood). 2016;241(3):290\u20135.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"7","key":"7558_CR5","first-page":"3016","volume":"86","author":"HB Burch","year":"2001","unstructured":"Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for graves\u2019 disease. J Clin Endocrinol Metab. 2001;86(7):3016\u201321.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"7558_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.7326\/0003-4819-121-8-199410150-00001","volume":"121","author":"HB Burch","year":"1994","unstructured":"Burch HB, Solomon BL, Wartofsky L, Burman KD. Discontinuing antithyroid drug therapy before ablation with radioiodine in graves disease. Ann Intern Med. 1994;121(8):553\u20139.","journal-title":"Ann Intern Med"},{"issue":"11","key":"7558_CR7","first-page":"4012","volume":"84","author":"VA Andrade","year":"1999","unstructured":"Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in graves\u2019 hyperthyroidism. J Clin Endocrinol Metab. 1999;84(11):4012\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7558_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0002-9343(83)91217-2","volume":"75","author":"MT McDermott","year":"1983","unstructured":"McDermott MT, Kidd GS, Dodson LE Jr., Hofeldt FD. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med. 1983;75(2):353\u20139.","journal-title":"Am J Med"},{"key":"7558_CR9","first-page":"8214169","volume":"2018","author":"K Vennard","year":"2018","unstructured":"Vennard K, Gilbert MP. Thyroid storm and complete heart block after treatment with radioactive iodine. Case Rep Endocrinol. 2018;2018:8214169.","journal-title":"Case Rep Endocrinol"},{"key":"7558_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.12659\/AJCR.890366","volume":"15","author":"HJ Rohrs","year":"2014","unstructured":"Rohrs HJ 3rd, Silverstein JH, Weinstein DA, Amdur RJ, Haller MJ. Thyroid storm following radioactive iodine (RAI) therapy for pediatric graves disease. Am J Case Rep. 2014;15:212\u20135.","journal-title":"Am J Case Rep"},{"issue":"5","key":"7558_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1210\/jcem.86.5.7473","volume":"86","author":"PM Kadmon","year":"2001","unstructured":"Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA. Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 2001;86(5):1865\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7592","key":"7558_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/bmj.39114.670150.BE","volume":"334","author":"MA Walter","year":"2007","unstructured":"Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334(7592):514.","journal-title":"BMJ"},{"issue":"5","key":"7558_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1055\/s-2006-924238","volume":"114","author":"SM Eschmann","year":"2006","unstructured":"Eschmann SM, Thelen MH, Dittmann H, Bares R. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of graves\u2019 disease: results of a prospective study. Exp Clin Endocrinol Diabetes. 2006;114(5):222\u20136.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8","key":"7558_CR14","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1210\/jc.2006-0226","volume":"91","author":"SJ Bonnema","year":"2006","unstructured":"Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab. 2006;91(8):2946\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"7558_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2362.2010.02452.x","volume":"41","author":"SJ Bonnema","year":"2011","unstructured":"Bonnema SJ, Grupe P, Boel-Jorgensen H, Brix TH, Hegedus L. A randomized trial evaluating a block-replacement regimen during radioiodine therapy. Eur J Clin Invest. 2011;41(7):693\u2013702.","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"7558_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3177\/jnsv.59.310","volume":"59","author":"M Tsubota-Utsugi","year":"2013","unstructured":"Tsubota-Utsugi M, Imai E, Nakade M, Matsumoto T, Tsuboyama-Kasaoka N, Nishi N, et al. Evaluation of the prevalence of iodine intakes above the tolerable upper intake level from four 3-day dietary records in a Japanese population. J Nutr Sci Vitaminol (Tokyo). 2013;59(4):310\u20136.","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"7558_CR17","unstructured":"Japan Thyroid Association. (2013) Guidelines for the diagnosis of thyroid disease 2013. http:\/\/www.japanthyroid.jp\/doctor\/guideline\/japanese.html accessed on September 6, 2021."},{"issue":"3","key":"7558_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.2016.0457","volume":"27","author":"EK Alexander","year":"2017","unstructured":"Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid: Official J Am Thyroid Association. 2017;27(3):315\u201389.","journal-title":"Thyroid: Official J Am Thyroid Association"},{"issue":"9","key":"7558_CR19","first-page":"3257","volume":"81","author":"Y Murakami","year":"1996","unstructured":"Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volume in response to radioactive iodine for graves\u2019 hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab. 1996;81(9):3257\u201360.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7558_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1507\/endocrj.EJ11-0279","volume":"59","author":"Y Osaki","year":"2012","unstructured":"Osaki Y, Sakurai K, Arihara Z, Hata M, Fukazawa H. Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with graves\u2019 disease. Endocr J. 2012;59(2):173\u20137.","journal-title":"Endocr J"},{"issue":"1","key":"7558_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"6","key":"7558_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/BF03348615","volume":"13","author":"C Marcocci","year":"1990","unstructured":"Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of graves\u2019 hyperthyroidism. J Endocrinol Invest. 1990;13(6):513\u201320.","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"7558_CR23","first-page":"1815","volume":"37","author":"R Aktay","year":"1996","unstructured":"Aktay R, Rezai K, Seabold JE, Bar RS, Kirchner PT. Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism. J Nucl Med. 1996;37(11):1815\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"7558_CR24","first-page":"2","volume":"13","author":"JW van Isselt","year":"2010","unstructured":"van Isselt JW, Broekhuizen-de Gast HS. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in graves\u2019 disease. Hell J Nucl Med. 2010;13(1):2\u20135.","journal-title":"Hell J Nucl Med"},{"issue":"6","key":"7558_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/RLU.0b013e3182817c78","volume":"38","author":"JA de Jong","year":"2013","unstructured":"de Jong JA, Verkooijen HM, Valk GD, Zelissen PM, de Keizer B. High failure rates after (131)I therapy in graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med. 2013;38(6):401\u20136.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"7558_CR26","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228\u201334.","journal-title":"Commun Stat Simul Comput"},{"issue":"1","key":"7558_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12020-020-02573-1","volume":"73","author":"M Finessi","year":"2021","unstructured":"Finessi M, Bisceglia A, Passera R, Rossetto Giaccherino R, Pagano L, Castellano G, et al. Predictive factors of a worse response to radioactive Iodine-I131 treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experience. Endocrine. 2021;73(1):107\u201315.","journal-title":"Endocrine"},{"issue":"1","key":"7558_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12902-018-0322-7","volume":"18","author":"E Fanning","year":"2018","unstructured":"Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves\u2019 disease: a 10-year Australian cohort study. BMC Endocr Disord. 2018;18(1):94.","journal-title":"BMC Endocr Disord"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-025-07558-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T18:27:44Z","timestamp":1763404064000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-025-07558-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7558"],"URL":"https:\/\/doi.org\/10.1186\/s13104-025-07558-9","relation":{},"ISSN":["1756-0500"],"issn-type":[{"type":"electronic","value":"1756-0500"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Clinical Research Ethics Committee of the University of Tsukuba Hospital (approval number: R06-018). Individual informed consent was waived by the ethics committee because this study used de-identified existing clinical records. An opt-out approach was implemented using a publicly available document to ensure participants had the opportunity to decline participation in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"476"}}